跳至主要内容
临床试验/EUCTR2020-001570-30-FR
EUCTR2020-001570-30-FR进行中(未招募)1 期

Interest of early treatment with polyvalent immunoglobulins in the management of respiratory distress syndrome associated with SARS-CoV-2 infections_COVID-19 - ICAR (IgIV in Covid-related ARds)

GHU PARIS PSYCHIATRIE ET NEUROSCIENCES0 个研究点目标入组 126 人开始时间: 2020年4月6日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
126

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) VM (mechanical ventilation) invasive for less than 36 hours
  • 2) ARDS meeting the Berlin criteria (Ref)
  • 3) SARS-CoV-2 infection proven by PCR
  • 4) Consent of the patient, a relative or relative or deferred (emergency clause).
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 126
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - Allergy to polyvalent immunoglobulins.
  • - Pregnant woman or minor patient
  • - Known IgA deficiency.
  • - Patient with renal failure on admission defined by a 3-fold increase in baseline creatinine or serum creatinine> 354 micromol / L or a diuresis of less than 0.3 mL / Kg for 24 hours or anuria for 12 hours.
  • - Participation in another interventional trial

研究者

发起方
GHU PARIS PSYCHIATRIE ET NEUROSCIENCES

相似试验